Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GB:GSK)
LSE:GSK
Holding GB:GSK?
Track your performance easily
GSK Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range1,371.40p - 1,823.50p
Previous Close1,419.5p
Volume679.50K
Average Volume (3M)7.53M
Market Cap
£57.90B
Enterprise Value70.19B
Total Cash (Recent Filing)£5.18B
Total Debt (Recent Filing)£18.02B
Price to Earnings (P/E)23.0
Beta0.54
Next Earnings
Feb 05, 2025EPS Estimate
£0.21Next Dividend Ex-Date
Nov 14, 2024Dividend Yield4.23%
Share Statistics
EPS (TTM)0.62
Shares Outstanding4,145,087,815
10 Day Avg. Volume8,753,563
30 Day Avg. Volume7,527,638
Standard Deviation0.07
R-Squared0.14
Alpha-0.00293
Financial Highlights & Ratios
Price to Book (P/B)409.08
Price to Sales (P/S)1.87
Price to Cash Flow (P/CF)14.20
P/FCF Ratio22.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
1,766.82pPrice Target Upside24.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
GlaxoSmithKline News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessGSK announced its Nucala COPD PIII trial (MATINEE) has met its primary endpoint, with a clinically meaningful and statistically significant reduction in exacerbations vs placebo in patients with baseline eosinophils >300 cells/uL.
Legal DevelopmentsThe interlocutory review by the Delaware Supreme Court is positive because GSK’s appeal met the high bar to hear the case, implying a reasonable chance the decision could be overturned.
Product PerformanceBepirovirsen has significant upside potential, especially if it successfully enters the Chinese market.
Bears Say
Growth ProjectionsGSK is projected to have one of the slowest growth rates in its sector post-2025, raising concerns about future performance.
Sales DeclineThe sales of Arexvy have dropped significantly, showing a 74% decrease year-over-year, which is well below consensus expectations.
Vaccine PerformanceGSK's vaccine segment faced a significant miss, with key drivers underperforming expectations.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.08% Insiders
11.07% Mutual Funds
<0.01% Other Institutional Investors
76.90% Public Companies and
Individual Investors
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest share price was 1371.40p and its highest was 1823.50p in the past 12 months.
What is GlaxoSmithKline’s market cap?
Currently, no data Available
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Feb 05, 2025 which is in 93 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Oct 30, 2024. The company reported 0.497p earnings per share for the quarter, beating the consensus estimate of 0.439p by 0.058p.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Annually dividend of 15p which represents an annual dividend yield of 4.23%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is £0.21.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 4,145,099,600 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of 0.497p in its last earnings report, beating expectations of 0.439p. Following the earnings report the stock price went down -3.066%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GB:GSK
---
GlaxoSmithKline Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
1,766.82p (24.80% Upside)
1,766.82p (24.80% Upside)
Insider Transactions
Bought Shares
Worth £99.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.56%
12-Months-Change
Fundamentals
Return on Equity
18.50%
Trailing 12-Months
Asset Growth
-4.62%
Trailing 12-Months
Company Description
GlaxoSmithKline
In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.
---
GSK Stock 12 Month Forecast
Average Price Target
1,766.82p
▲(24.80% Upside)
Technical Analysis
Best Analysts Covering GSK
1 Year
1 Year Success Rate
21/38 ratings generated profit
1 Year Average Return
+2.88%
reiterated a buy rating 5 days ago
Copying Emmanuel Papadakis's trades and holding each position for 1 Year would result in 55.26% of your transactions generating a profit, with an average return of +2.88% per trade.
---